Printable wording
A formulation with gelling agents, thickening agents, and lipid-based excipients addresses the challenge of 3D printability by ensuring uniform deposition and maintaining formulation integrity, improving handling and reducing solvent evaporation.
Patent Information
- Application Number
- FR2023001696
- Authority / Receiving Office
- FR · FR
- Patent Type
- Utility models
- Current Assignee / Owner
- Priority Date
- 2022-12-22
- Filing Date
- 2023-02-24
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2033-02-24
AI Technical Summary
The development of ink formulations for 3D printing in pharmaceuticals is hindered by the need for printable materials with specific physicochemical properties that allow printing at moderate temperatures while being solid at room temperature, affecting printability.
A formulation comprising 2 to 30% gelling agents, 1 to 10% thickening agents, 1 to 40% lipid-based excipients, 40 to 70% solvents, and optionally preservatives, pH adjusters, and flavoring agents, with lipid-based excipients like cocoa butter and coconut oil, to achieve thermoreversible viscosity for printing.
Improves 3D printability by ensuring uniform deposition, controlled extrusion, and maintains formulation integrity and mechanical properties, enhancing handling and reducing solvent evaporation, with improved mass variation and mouthfeel.
Abstract
Description
Title of the invention: Printable formulation Technical field
[0001] The present disclosure relates to formulations that are suitable for 3D printing, in particular formulations comprising one or more lipid-based excipients.
[0002] BACKGROUND
[0003] Three-dimensional (3D) printing is a technology that enables the manufacturing of customized pharmaceutical forms of drugs. The main benefit of using 3D printing technology for customized pharmaceutical products is the ability to produce small batches with carefully tailored dosages, shapes, sizes, and release characteristics. It also allows flavors to be incorporated into a tablet without the need for film coating, completely masking the taste of the chemical compounds. 3D printers can be installed in pharmacies, hospitals, clinics, and remote locations, allowing for on-demand production of drugs, especially those with poor stability or cold chain storage requirements.For pharmaceutical companies, 3D printing can significantly reduce costs, waste, and environmental constraints because printers only deposit the exact amount of raw materials needed.
[0004] The main challenge of the 3D printing process is the development of the ink itself because its physicochemical properties could strongly affect the printability. The ink must be printable at a moderate temperature while being solid at room temperature.
[0005] Thus, there is still a need for other printable formulations for drugs.
[0006] SUMMARY
[0007] It has been observed that when a portion of the thickening agents in a formulation are replaced with one or more lipid-based excipients, the 3D printability of the formulation can be improved.
[0008] Thus, an object of the present invention is to provide a printable formulation comprising
[0009] - 2 to 30% by weight of one or more gelling agents,
[0010] - 1 to 10% by weight of one or more thickening agents,
[0011] - 1 to 40% by weight, preferably 10 to 35% by weight of one or more excipients lipid base, and
[0012] - 40 to 70% by weight of one or more solvents.
[0013] A number of exemplary and non-limiting embodiments of the invention are described in the appended dependent claims.
[0014] Various exemplary non-limiting embodiments of the invention and methods of operation, as well as additional objects and advantages, are better understood in the following description of specific exemplary embodiments, when read in conjunction with the accompanying figures.
[0015] The verbs "comprise" and "include" are used herein as open limitations that neither exclude nor require the existence of features also not mentioned. The features recited in the dependent claims are freely combinable with each other unless explicitly indicated otherwise. Furthermore, it is understood that the use of "a" or "an", i.e. a singular form, throughout this document does not exclude a plurality.
[0016] EXPLANATION OF THE INVENTION
[0017] The specific examples provided in the description given below should not be construed as limiting the scope and / or applicability of the appended claims. The lists and groups of examples provided in the description given below are not exhaustive unless explicitly stated otherwise.
[0018] According to one aspect the present description relates to a formulation comprising
[0019] - 2 to 30% by weight of one or more gelling agents,
[0020] - 1 to 10% by weight of one or more thickening agents,
[0021] - 1 to 40% by weight, preferably 10 to 35% by weight of one or more excipients lipid base,
[0022] - 40 to 70% by weight of one or more solvents, and optionally
[0023] - one or more preservatives, pH adjusting agents, and / or flavoring agents.
[0024] The gelling agents are preferably selected from a group consisting of gelatin, pullulan, carrageenan and agar-agar. According to one embodiment the gelling agent is gelatin, and the formulation comprises 5 to 30% by weight of gelatin. According to another embodiment the gelling agent is agar-agar, and the formulation comprises 5 to 10% of agar-agar, such as 6% by weight of agar-agar.
[0025] The thickening agents are preferably selected from a group consisting of mannitol, cellulose and silica. The cellulose may be microcrystalline cellulose (MCC).
[0026] The formulation comprises one or more lipid-based excipients. Exemplary lipid-based excipients suitable for the formulation are cocoa butter, coconut oil, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, and polyethylene glycol fatty acid esters. Preferable lipid-based excipients are cocoa butter and coconut oil. Mixtures of one or more ex- Lipid-based containers can also be used.
[0027] The formulation comprises one or more solvents. Preferable solvents are water and glycerol. In one exemplary embodiment the formulation comprises 40-50 wt% water and 5-6 wt% glycerol. A higher amount of solvent such as 50 wt% or more may be preferable when there is a need to achieve high solubilization of API in the formulation. However, the presence of excessively high levels of solvent, especially water levels but also one or more of other near infrared (NIR) absorbing elements such as thickeners, other solvents, and fillers should be avoided if NIR is used for quality control of the formulation.
[0028] The formulation may also include one or more preservatives, one or more pH adjusting agents, and one or more flavoring agents. Exemplary pH adjusting agents are citric acid, sodium citrate, and malic acid. Exemplary preservatives are sorbic acid, potassium sorbate, and parabens. Exemplary flavoring agents are selected from beef flavor, bacon flavor, lamb flavor, chicken flavor, chicken liver flavor, cheese flavor, cod liver oil flavor, marshmallow flavor, molasses flavor, vanilla flavor, peanut butter flavor, fruit flavor, and berry flavor.
[0029] Typically the formulation may comprise up to 1% by weight of preservatives, up to 1% by weight of pH adjusting agents and up to 5% by weight of flavoring agents of the total weight of the formulation.
[0030] According to a preferable embodiment, the formulation comprises one or more sweetening agents selected from the group of polyol sugars which are not metabolized in the same manner as normal carbohydrates and have fewer calories than sugar. An exemplary polyol sugar is erythritol.
[0031] It is essential that the printing formulation be thermoreversible. Its viscosity at the printing temperature must allow printing at a moderate temperature such as 40 to 50 °C, while it must be solid at room temperature. The viscosity of the formulation of the present description at 50 °C (shear rate 150 to 800) preferably ranges from 2 to 4 Pas.
[0032] According to a particular embodiment the formulation comprises one or more active pharmaceutical ingredients (APIs). Exemplary APIs are selected from a group consisting of sildenafil, caffeine, prednisolone, gabapentin, ursodeoxycholic acid, atenolol, theophylline, diltiazem, hydrochlorothiazide, propranolol, metoprolol, metronidazole, captopril, furosemide, and pharmaceutically acceptable salts thereof. The formulation typically comprises from 0.1 wt% to 10 wt% of one or more APIs, wherein the wt% is the total wt% of the APIs. in the formulation.
[0033] The formulation employed has a marked influence on the release of the active ingredient incorporated therein. The ratio of lipid-based excipient is preferably 10 to 35% by weight for more precise control of viscoelastic behavior and ease of processing. If the ratio is lower the consistency is less favorable due to low viscosities at optimal processing temperatures. With higher weight %, separation of the oil and water phase is more likely to occur. Also, higher temperatures may be required due to the increased viscosity. Furthermore, with too high a weight % of the lipid-based excipient in the oral preparation the fat-like consistency and taste may be unpleasant.
[0034] The solid dosage formulation may be prepared by a process comprising
[0035] - providing a formulation comprising
[0036] - 2 to 30% by weight of one or more gelling agents,
[0037] - 1 to 10% by weight of one or more thickening agents,
[0038] - 1 to 40% by weight, preferably 10 to 35% by weight of one or more excipients lipid base,
[0039] - 40 to 70% by weight of one or more solvents, and
[0040] - 0.1 to 10% by weight of one or more active pharmaceutical ingredients (API),
[0041] - heating the formulation to a temperature of at least 37°C,
[0042] - using a 3D printer, printing the formulation at least at 37°C on a printing substrate,
[0043] - cooling the formulation to 30°C or less, and
[0044] - releasing the formulation from the printing substrate which provides the formulation solid dosage.
[0045] According to one embodiment the API(s) are included in the formulation during the process of manufacturing the formulation. According to another embodiment the API(s) are mixed with a prefabricated formulation. Exemplary non-limiting API(s) suitable for the present disclosure are sildenafil, caffeine, pred-nisolone, gabapentin, ursodeoxycholic acid, atenolol, theophylline, diltiazem, hydrochlorothiazide, propranolol, metoprolol, metronidazole, captopril, furosemide, and pharmaceutically acceptable salts thereof.
[0046] When API is added to the formulation its effect on viscosity will depend on the phase it is going to i.e., lipophilic drugs in the lipid phase and hydrophilic in the aqueous / hydrophilic phase. Similarly, the properties of API can decrease or increase viscosity. The effects are governed by the solubility of the drugs in the matrix and hydrogen bonding. Substances that are capable of forming hydrogen bonds tend to have a higher viscosity. higher than those that do not form hydrogen bonds. Generally, substances that have the potential for multiple hydrogen bonds have even higher viscosities. The hydrogen bonding potential is higher with higher concentrations and vice versa.
[0047] It is essential that the mixture be heated to 37°C or higher to ensure adequate printing. The printing temperature is preferably between 37°C and 55°C. An exemplary printing temperature is 40°C. Another exemplary printing temperature is 45°C.
[0048] The mixture is printed onto a printing substrate which is preferably positioned inside the 3D printer. When printing is complete, the mixture is solidified upon cooling, for example by decreasing the temperature to 30°C or less. Experimental section
[0049] 3D printing
[0050] Printing was implemented using a commercial 3D printer (Foodini by Natural Machines) equipped with ink supply cartridges, heaters, nozzles, control software and a print base. Typical print parameters were as follows:
[0051] Nozzle size 1.5 mm
[0052] Printing speed 1500 to 4000 mm / min
[0053] Ingredient flow rate 2 m / min
[0054] Ingredient flow temp. 40 to 50°C
[0055] Preheating temp. 40 to 50 °C
[0056] Ingredient holding 0.2 to 2.5 mm
[0057] Preheating time 30 to 60 s
[0058] First layer nozzle height 10 mm
[0059] Distance between layers 1.4 mm
[0060] An exemplary printable formulation according to the present disclosure is shown in Table 1. The comparative formulation was as shown in Table 1, but the cocoa butter was replaced with mannitol.
[0061] Table 1 Ingredients: Quantity (g) % g / g Gelatin 12.42 12.42 0.1242 Purifying aq. 42.39 42.39 0.4239 Glycerol 5.59 5.59 0.0559 Potassium sorbate 0.15 0.15 0.0015 Citric Acid 0.47 0.47 0.0047 Sodium Citrate 0.47 0.47 0.0047 Sucralose 0.048 0.05 0.0005 Xylitol 20.38 20.38 0.2038 Maltodextrin 4.23 4.23 0.0423 Cocoa Butter 12.23 12.23 0.1223 Silicon Dioxide 1.23 1.23 0.0123 Raspberry Flavor 0.15 0.15 0.0015 Vanilla Flavor 0.23 0.23 0.0023 early 100.00 100.00 1.00 Observations
[0062] * The printable formulation comprising a lipid-based excipient produced more uniform printing from tablet to tablet. Extrusion was more controllable and the stream of material exiting the nozzle was cut in a controlled / uniform manner without unwanted dripping, which allowed for uniform deposition of the formulation. Similarly, there was much less extrusion of the formulation into the bin before the start of each print job.
[0063] • The addition of lipid-based excipient does not hinder the solubility of IPA hydro soluble. The formulation is homogeneous without separation for up to one month at room temperature. The mechanical properties are even favorable, making handling easier and less sticky.
[0064] * Mass variation, physical appearance and mouthfeel also have been improved.
[0065] • The water retention quality (the evaporation of water / solvent by the formulation is much lower) of the final formulation has been significantly improved. The formulations can retain their physical integrity and mechanical properties for a longer period when exposed to open air compared to the comparative formulation.
Claims
Claims
1. Printable formulation comprising - 2 to 30% by weight of one or more gelling agents, - 1 to 10% by weight of one or more thickening agents, - 1 to 40% by weight, preferably 10 to 35% by weight of one or more lipid-based excipients, and - 40 to 70% by weight of one or more solvents.
2. A printable formulation according to claim 1 wherein the lipid-based excipient(s) are selected from a group consisting of cocoa butter, coconut oil, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, polyethylene glycol fatty acid esters, and mixtures thereof, preferably from cocoa butter and coconut oil and mixtures thereof.
3. A printable formulation according to claim 1 or 2 wherein the gelling agent(s) are selected from a group consisting of gelatin, pullulan, carrageenan and agar-agar, preferably gelatin.
4. A printable formulation according to any one of claims 1 to 3 wherein the thickening agent(s) are selected from a group consisting of mannitol, cellulose and silica.
5. A printable formulation according to any one of claims 1 to 4 wherein the solvent(s) are selected from water and glycerol.
6. A printable formulation according to any one of claims 1 to 5 comprising one or more preservatives, one or more pH adjusting agents, and / or one or more flavoring agents.
7. A printable formulation according to claim 6 wherein the preservative(s) are selected from sorbic acid, potassium sorbate, and para-hydroxybenzoates.
8. A printable formulation according to claim 6 or 7 wherein the pH adjusting agent(s) are selected from citric acid, sodium citrate, and malic acid.
9. A printable formulation according to any one of claims 6 to 8 wherein the flavoring agent(s) is / are selected from a group consisting of beef flavor, bacon flavor, lamb flavor, chicken flavor, chicken liver flavor, cheese flavor, cod liver oil flavor, marshmallow flavor, molasses flavor, vanilla flavor, peanut butter flavor, fruit flavor, and cherry flavor.
10. A printable formulation according to any one of claims 6 to 9 wherein the flavoring agent(s) comprise one or more polyol sugars.
11. A printable formulation according to any one of claims 1 to 10 comprising 0.1 to 10% by weight of one or more active pharmaceutical ingredients (APIs).
12. A printable formulation according to any one of claims 1 to 11, wherein the viscosity of the printable formulation at 50°C is from 2 to 4 Pas.
13. A formulation according to claim 12 wherein the API(s) is / are selected from a group consisting of sildenafil, caffeine, prednisolone, gabapentin, ursodeoxycholic acid, atenolol, theophylline, diltiazem, hydrochlorothiazide, propranolol, metoprolol, metronidazole, captopril, furosemide, and pharmaceutically acceptable salts thereof.
